Studie zur Therapie beim metastasierten kastrationsresistenten Prostatakarzinom (VIABLE)A Randomized, Double Blind, Multicenter, Parallel-Group, Phase III Study to Evaluate Efficacy and Safety of DCVAC/PCa Versus Placebo in Men with Metastatic Castration Resistant Prostate Cancer Eligible for 1st Line Chemotherapy (VIABLE) – AP 78/13 der AUO

被引：0

作者：

H. Rexer

机构：

[1] Arbeitsgemeinschaft Urologische Onkologie (AUO),

来源：

Forum | 2016年 / 31卷 / 1期

关键词：

D O I：

10.1007/s12312-015-0005-5

中图分类号：

学科分类号：

摘要：

引用

页码：63 / 64

页数：1

共 4 条

[1] Studie zur Therapie beim metastasierten kastrationsresistenten ProstatakarzinomParallelgruppendesign zur Analyse der Wirksamkeit und Sicherheit von DCVAC/PCa vs. Placebo bei Männern mit metastasiertem kastrationsresistentem Prostatakarzinom und Eignung für die Erstlinienchemotherapie (VIABLE) – AUO-Studie AP 78/13Study and therapy of metastatic castration-resistant prostate cancerA randomized, double blind, multicenter, parallel-group, phase III study to evaluate efficacy and safety of DCVAC/PCa versus placebo in men with metastatic castration resistant prostate cancer eligible for first line chemotherapy (VIABLE) – AUO study AP 78/13
H. Rexer
Der Urologe, 2015, 54 (4): : 555 - 557
[2] Study on the therapy of castration-resistant prostate cancer: Randomized phase II study of abiraterone acetate plus LHRH therapy vs. abiraterone acetate without LHRH therapy in patients with progressive chemotherapy-naïve castration-resistant prostate cancer [SPARE – AP 67/11 of the Association of Urogenital Oncology (AUO)] [Studie zur Therapie beim kastrationsresistenten Prostatakarzinom: Randomisierte Phase-II-Studie von Abirateronacetat plus LHRH-Therapie vs. Abirateronacetat ohne LHRH-Therapie bei Patienten mit progressivem chemotherapienaivem kastrationsresistentem Prostatakarzinom (SPARE – AP 67/11 der AUO)]
Rexer H.
Der Urologe, 2014, 53 (11): : 1665 - 1667
[3] TRITON 2: Drittlinientherapie beim metastasierten kastrationsrefraktären Prostatakarzinom (mCRPC)Eine internationale, multizentrische, offene Phase-2-Studie des PARP-Inhibitors Rucaparib an Patienten mit metastasiertem kastrationsresistentem Prostatakarzinom (mCRPC) in Verbindung mit einer Störung der homologen Rekombination (TRITON2) – AP 99/18 der AUOTRITON 2: Third line therapy in patients with metastatic castration-resistant prostate cancer (mCRPC)An international, multicenter, open-label Phase 2 study of the PARP inhibitor rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) associated with a homologous recombination deficiency (TRITON2) – AP 99/18 in AUO
H. Rexer
P. Hammerer
A. Merseburger
Forum, 2019, 34 (1) : 77 - 79
[4] Second-line Therapy after Failure of Next-Generation-Hormone Therapy (NHA) for Patients with metastatic castration-resistant Prostate Cancer (mCRPC) Randomized, double-blind phase-III-Study on Pembrolizumab (MK-3475), Docetaxel and Prednisone Combination versus Placebo, Docetaxel and Prednisone Combination for Patients with chemotherapy-naive metastatic castration-resistant Prostate Cancer (mCRPC) with Progression under a Hormone Preparation of the next Generation (KeyNote 106/1921) - AP 106/1921 of the AUO
Rexer, H.
Gratzke, C.
Graefen, M.
AKTUELLE UROLOGIE, 2021, 52 (01) : 26 - 27

← 1 →